Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Csl Ltd ADR
(OP:
CSLLY
)
104.28
-1.01 (-0.96%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Csl Ltd ADR
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
July 04, 2024
From
CSL Behring
Via
GlobeNewswire
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
From
Arcturus Therapeutics
Via
Business Wire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
April 30, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
November 02, 2022
Via
Benzinga
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
August 17, 2022
Via
Benzinga
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
April 26, 2024
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.
Via
Benzinga
Exposures
Product Safety
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
April 03, 2024
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Via
MarketBeat
Exposures
Product Safety
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
February 05, 2024
From
Arcturus Therapeutics
Via
Business Wire
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
December 21, 2023
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
December 13, 2023
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.
Via
Benzinga
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
November 28, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 18, 2023
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in...
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
OTC Markets Group Welcomes CSL Limited to OTCQX
April 27, 2023
From
OTC Markets
Via
GlobeNewswire
5 Diverse Medical Stocks To Buy For 2023 And Beyond
April 08, 2023
Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and...
Via
Talk Markets
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
March 20, 2023
Reuters
Via
Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
March 20, 2023
Via
Benzinga
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
Why CSL Ltd Stock Could Be Worth a Look
December 03, 2022
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.
Via
MarketBeat
Exposures
Product Safety
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
November 23, 2022
Via
Benzinga
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
November 02, 2022
The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology.
Via
InvestorPlace
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
August 22, 2022
Via
Benzinga
Finalization of Vifor Pharma acquisition
August 02, 2022
From
Vifor Pharma AG
Via
Business Wire
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021
December 14, 2021
Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.